CSPC Pharmaceutical GroupCSPCY +9.27%76 PB Ratio is 2.17 as of Jun. 30, 2026, which is 40% below its 10-year median of 3.60. GuruFocus rates CSPCY with a GF Score™ of 76/100 and a GF Value™ of $3.37 (Fairly Valued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks worse than 56.2% on this metric.
CSPC Pharmaceutical Group Ltd stock PB Ratio (=2.17) is close to 1-year low of 2.08.
The historical rank and industry rank for CSPC Pharmaceutical Group's PB Ratio or its related term are showing as below:
CSPCY'
s PB Ratio Range Over the Past 10 Years
Min: 1.43 Med: 3.6 Max: 8.65
Current: 2.17
During the past 13 years, CSPC Pharmaceutical Group's highest PB Ratio was 8.65. The lowest was 1.43. And the median was 3.60.
CSPCY's PB Ratio is ranked worse than 56.2% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.845
vs CSPCY: 2.17
During the past 12 months, CSPC Pharmaceutical Group's average Book Value Per Share Growth Rate was 7.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CSPC Pharmaceutical Group was 54.40% per year. The lowest was -41.70% per year. And the median was 15.90% per year.
Back to Basics: PB Ratio
CSPC Pharmaceutical Group (OTCPK:CSPCY) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CSPC Pharmaceutical Group PB Ratio Related Terms
CSPC Pharmaceutical Group PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CSPC Pharmaceutical Group (CSPCY) has a PB Ratio of 2.17 as of Jun. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CSPC Pharmaceutical Group and its competitors. This is 40% below median its historical median of 3.60. Over the past decade, CSPC Pharmaceutical Group's PB Ratio has ranged from 1.43 to 8.65. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #517 out of 920 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is CSPC Pharmaceutical Group's PB Ratio too high?
CSPC Pharmaceutical Group's current PB Ratio of 2.17 is 40% below median its 10-year median of 3.60. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 8.65. The Drug Manufacturers industry median PB Ratio is 1.85. CSPC Pharmaceutical Group's value of 2.17 is 17.6% above this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #517 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #517 out of 920 companies for PB Ratio. This places CSPC Pharmaceutical Group in the lower half of its industry. The industry median PB Ratio is 1.85. CSPC Pharmaceutical Group's value of 2.17 is 17.6% above this benchmark. Historically, CSPC Pharmaceutical Group's own PB Ratio has ranged from 1.43 to 8.65 over the past decade. While the company's 10-year median is 3.60 vs. the industry median of 1.85, CSPC Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.85, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current PB Ratio of 2.17 is 17.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current PB Ratio is 2.17, which is 40% below median its own 10-year median of 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Fairly Valued. The stock's GF Value™ is $3.37, compared to a current price of $3.58 — trading 6.4% above its estimated fair value. The current PB Ratio is 2.17, which is 40% below median its 10-year median of 3.60 and 17.6% above the Drug Manufacturers industry median of 1.85. CSPC Pharmaceutical Group's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current PB Ratio is 2.17 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $3.58 is trading 6.4% above its estimated GF Value™ of $3.37.
GuruFocus considers CSPC Pharmaceutical Group to be Fairly Valued.
Key valuation signals for CSPCY:
PB Ratio: 2.17 (40% below median its 10-year median of 3.60)
GF Value™: $3.37 vs. price of $3.58 (6.4% above fair value)
Industry Position: 17.6% above the Drug Manufacturers median (#517 of 920)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
76GF Score
Get the complete analysis for CSPCY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
